GlassScriptPhysician profile
Robert M Miller
NPI 1801892443
$2,657.08
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $964 · 2021: $763 · 2022: $13.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $264.18 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $258.07 | 2019-2021 | |
| Pfizer INC. | $225.88 | 2019-2020 | |
| Allergan, INC. | $210.21 | 2019-2020 | |
| Abbvie INC. | $209.02 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $207.77 | 2019-2021 | |
| Novo Nordisk INC | $131.64 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $101.16 | 2020-2021 | |
| Amgen INC. | $98.04 | 2019-2020 | |
| Glaxosmithkline, LLC. | $92.65 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $84.56 | 2019-2021 | |
| Astellas Pharma US INC | $81.09 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $76.04 | 2019 | |
| Adlon Therapeutics L.P. | $71.57 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.14 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $47.67 | 2019 | |
| Neos Therapeutics, LP | $36.96 | 2020 | |
| Novartis Pharmaceuticals Corporation | $36.14 | 2019 | |
| Genentech USA, INC. | $33.05 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $30.85 | 2021 | |
| Eisai INC. | $27.87 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.13 | 2019-2020 | |
| Orexo US, INC. | $25.13 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $23.07 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $22.54 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.17 | 2019 | |
| Lilly USA, LLC | $17.07 | 2019 | |
| Abbott Laboratories | $16.97 | 2020 | |
| Dexcom, INC. | $13.43 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.33 | 2019 | |
| Seqirus USA INC | $13.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.96 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.